Abstract
A total of 24 liver metastases of colorectal cancer were evaluated by dynamic multiphasic
CT. Under chemotherapy, follow-up examinations were performed every 3 months. The
tumor marker CEA before vs. after chemotherapy correlated with the mean contrast enhancement
within the margin of metastases. The total size of metastases correlated with the
size of central necrosis as well as with the size of marginal contrast enhancement.
CT is able to quantify perfusion and local activity of liver metastases to determine
the efficacy of chemotherapy.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical ImagingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global cancer statistics.CA Cancer J Clin. 1999; 49: 33-64
- Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control.J Natl Cancer Inst. 2003; 95: 1276-1299
- The role of chemotherapy in the curative treatment of patients with liver metastases from colorectal cancer.Surg Oncol Clin N Am. 2007; 16: 537-556
- Neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer.Expert Rev Anticancer Ther. 2007; 7: 887-897
- Treatment options for liver metastases from colorectal cancer.J Exp Clin Cancer Res. 2003; 22: 149-156
- Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use.Eur J Cancer. 2007; 43: 1348-1360
- Detection of liver metastases in colorectal cancer on chemotherapy. Comparative study between MRI with teslascan and computed tomography with intravenous contrast media.J Radiol. 2004; 85: 307-311
- Liver metastases of colorectal cancer: US, CT or MR?.Cancer Imaging. 2005; 23: S149-S156
- Radiological staging of colorectal liver metastases.Surg Oncol. 2007; 16: 7-14
- Detection and characterisation of liver metastases.Eur Radiol. 2004; 14: P25-P33
- Ultrasonographic detection of focal liver lesions: increased sensitivity and specificity with microbubble contrast agents.Eur J Radiol. 2003; 46: 147-159
- Liver metastases in cancer: detection with contrast-enhanced ultrasonography.Abdom Imaging. 2004; 29: 669-681
- Ultrasound during follow-up of carcinoma.Chirurg. 2007; 78: 449-453
- Assessment of metastatic liver disease in patients with primary extrahepatic tumors by contrast-enhanced sonography versus CT and MRI.World J Gastroenterol. 2006; 12: 1699-1705
- Comparison of CT during arterial portography and MR during arterial portography in the detection of liver metastases.AJR Am J Roentgenol. 2006; 186: 1502-1511
- Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue—initial experience.Radiology. 2007; 243: 736-743
- Perfusion imaging of the liver: current challenges and future goals.Radiology. 2005; 234: 661-673
- CT of colon cancer metastases to the liver using modified RECIST criteria: determining the ideal number of target lesions to measure.AJR Am J Roentgenol. 2006; 186: 1067-1070
- Using triphasic helical CT to detect focal hepatic lesions in patients with neoplasms.AJR Am J Roentgenol. 1998; 171: 643-649
- The value of different spiral CT phases in the detection of liver metastases.Fortschr Roentgenstr. 2002; 174: 452-458
- Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.J Clin Oncol. 2003; 21: 3955-3964
- Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil.NMR Biomed. 2007; 20: 128-140
- PET-FDG as predictor of therapy response in patients with colorectal carcinoma.Q J Nucl Med. 2003; 47: 8-13
- Dose rates in diagnostic radiology.Dtsch Arztebl. 2003; 100: 2087-2088
- CT radiation exposure risk in Germany.Fortschr Roentgenstr. 2001; 173: R1-R66
Article info
Publication history
Published online: November 27, 2008
Accepted:
October 8,
2008
Received:
September 1,
2008
Identification
Copyright
© 2009 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
